StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NYSE:NBY opened at $0.63 on Monday. The business has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.63. The firm has a market cap of $3.08 million, a price-to-earnings ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.